Martin J Rosenberg

US Patent:

7173110, Feb 6, 2007

Filed:

Oct 31, 2005

Appl. No.:

11/264684

Inventors:

Martin J. Rosenberg - Brooklyn NY, US

Assignee:

New York University - New York NY

International Classification:

A61K 38/04
A61K 38/12

US Classification:

530328, 530317

Abstract:

Disclosed herein are isolated, purified peptides, biologically active fragments and analogs of the peptides having anti-tumor activity in mammals, pharmaceutical formulations comprising the peptides, fragments and analogs and methods of treating mammals suffering from tumors using such materials.

US Patent:

7691964, Apr 6, 2010

Filed:

Dec 22, 2006

Appl. No.:

11/615723

Inventors:

Martin Jay Rosenberg - Brooklyn NY, US

Assignee:

New York University - New York NY

International Classification:

A61K 38/12
A61K 38/00
A61K 51/00

US Classification:

530317, 514 2, 424 169

Abstract:

Disclosed herein are isolated, purified peptides, biologically active fragments and analogs of the peptides having anti-tumor activity in mammals, pharmaceutical formulations comprising the peptides, fragments and analogs and methods of treating mammals suffering from tumors using such materials.

US Patent:

8003598, Aug 23, 2011

Filed:

Dec 28, 2009

Appl. No.:

12/647899

Inventors:

Martin Jay Rosenberg - Brooklyn NY, US

Assignee:

New York University - New York NY

International Classification:

A61K 38/00
A61K 51/00

US Classification:

514 11, 530317, 424 169

Abstract:

Disclosed herein are isolated, purified peptides, biologically active fragments and analogs of the peptides having anti-tumor activity in mammals, pharmaceutical formulations comprising the peptides, fragments and analogs and methods of treating mammals suffering from tumors using such materials.

US Patent:

20030124507, Jul 3, 2003

Filed:

Mar 13, 2002

Appl. No.:

10/099198

Inventors:

Andrea Marra - Menlo Park CA, US
Martin Rosenberg - Royersford PA, US
Yinduo Ji - Spring City PA, US

Assignee:

SmithKline Beecham Corporation

International Classification:

C12Q001/00
C12Q001/68
C12N015/74
C12N001/21

US Classification:

435/004000, 435/006000, 435/471000, 435/252300

Abstract:

The present invention provides a method for determining pathogen sensitivity to varying levels of reduction of a gene product using an expression vector system having a promoter that is essentially off in vitro and turns on selectively during the infection process in vivo. Genes and gene products identified by this method as essential to growth of infection of a selected pathogen are also provided. In addition, therapeutic compositions designed to target genes identified by this method are provided.

US Patent:

20050095643, May 5, 2005

Filed:

Dec 20, 2004

Appl. No.:

11/017379

Inventors:

Andrea Marra - Menlo Park CA, US
Martin Rosenberg - Royersford PA, US
Yinduo Ji - Spring City PA, US

International Classification:

C12Q001/68
C12N015/85

US Classification:

435006000, 435455000

Abstract:

The present invention provides a method for determining pathogen sensitivity to varying levels of reduction of a gene product using an expression vector system having a promoter that is essentially off in vitro and turns on selectively during the infection process in vivo. Genes and gene products identified by this method as essential to growth of infection of a selected pathogen are also provided. In addition, therapeutic compositions designed to target genes identified by this method are provided.

US Patent:

20050124531, Jun 9, 2005

Filed:

Feb 24, 2003

Appl. No.:

10/505715

Inventors:

George Lipkin - New York NY, US
Martin Rosenberg - Brooklyn NY, US

Assignee:

New York University - New YorK NY

International Classification:

A61K038/18
A61K031/7072
A61K031/704
A61K031/337

US Classification:

514002000, 514027000, 514049000, 514034000, 514449000

Abstract:

The present invention is directed to a method for treating a patient suffering from inappropriate or excessive angio-genic activity comprising on administering to a patient in need of such treatment an amount of Contact Inhibitory Factor effective to treat said disease. Also disclosed herein are methods for preventing a cancer cell from metastasizing comprising administering to a patient in need of such treatment Contact Inhibitory Factor and a chemtherapeutic or immunotherapeutic agent. Also disclosed are pharmaceutical formulations for use in the methods.

US Patent:

43070825, Dec 22, 1981

Filed:

Jul 10, 1979

Appl. No.:

6/056393

Inventors:

Martin J. Rosenberg - Brooklyn NY

Assignee:

New York University - New York NY

International Classification:

A61K 3500
C12P 100

US Classification:

424115

Abstract:

Described herein is a method for the extraction of an active biochemical factor that restores contact inhibition of growth to malignant cell types of different mammalian species.

US Patent:

45307849, Jul 23, 1985

Filed:

Aug 19, 1983

Appl. No.:

6/524917

Inventors:

Martin J. Rosenberg - Brooklyn NY

Assignee:

New York University - New York NY

International Classification:

A61K 3500

US Classification:

260112R

Abstract:

A method for extracting large quantities of an active biological factor that restores contact inhibition of growth to malignant cell types of different mammalian species.